KR20130136988A - 지혈 장애를 치료하기 위한 인자 ii 및 피브리노겐 - Google Patents

지혈 장애를 치료하기 위한 인자 ii 및 피브리노겐 Download PDF

Info

Publication number
KR20130136988A
KR20130136988A KR1020137008520A KR20137008520A KR20130136988A KR 20130136988 A KR20130136988 A KR 20130136988A KR 1020137008520 A KR1020137008520 A KR 1020137008520A KR 20137008520 A KR20137008520 A KR 20137008520A KR 20130136988 A KR20130136988 A KR 20130136988A
Authority
KR
South Korea
Prior art keywords
fii
fibrinogen
coagulation
fviia
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137008520A
Other languages
English (en)
Korean (ko)
Inventor
안 로브그렌
케니 한손
Original Assignee
메디뮨 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130136988(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 메디뮨 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20130136988A publication Critical patent/KR20130136988A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020137008520A 2010-10-06 2011-09-19 지혈 장애를 치료하기 위한 인자 ii 및 피브리노겐 Ceased KR20130136988A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06
US61/390,224 2010-10-06
PCT/EP2011/066241 WO2012045569A1 (en) 2010-10-06 2011-09-19 Factor ii and fibrinogen for treatment of haemostatic disorders

Publications (1)

Publication Number Publication Date
KR20130136988A true KR20130136988A (ko) 2013-12-13

Family

ID=44677879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137008520A Ceased KR20130136988A (ko) 2010-10-06 2011-09-19 지혈 장애를 치료하기 위한 인자 ii 및 피브리노겐

Country Status (16)

Country Link
US (1) US9433664B2 (enExample)
EP (1) EP2624859B1 (enExample)
JP (1) JP6000259B2 (enExample)
KR (1) KR20130136988A (enExample)
CN (1) CN103221061A (enExample)
AU (1) AU2011313505B2 (enExample)
BR (1) BR112013008034A2 (enExample)
CA (1) CA2812888A1 (enExample)
DK (1) DK2624859T3 (enExample)
ES (1) ES2625153T3 (enExample)
HU (1) HUE033204T2 (enExample)
MX (1) MX343784B (enExample)
PL (1) PL2624859T3 (enExample)
RU (1) RU2606155C2 (enExample)
SG (2) SG188639A1 (enExample)
WO (1) WO2012045569A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171463B2 (en) 2008-10-03 2024-12-24 Femasys Inc. Contrast agent generation and injection system for sonographic imaging
WO2012045569A1 (en) 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders
IL230150A0 (en) * 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
AU2018217375B2 (en) * 2017-02-09 2024-04-18 Csl Behring Gmbh A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002105A1 (en) 1980-01-28 1981-08-06 Baxter Travenol Lab Therapeutic compositions & methods for manufacture and use
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DE59712322D1 (de) 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
WO2002062377A2 (en) 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
AU2002354846B2 (en) 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20040101546A1 (en) 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
JP2006515309A (ja) 2002-12-31 2006-05-25 マリン ポリマー テクノロジーズ，インコーポレーテッド 止血剤組成物およびその使用
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ES2399277T3 (es) 2004-05-27 2013-03-27 Baxter International Inc. Procedimiento de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
EP1893230A2 (en) 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CN101501216B (zh) * 2006-03-06 2013-10-02 胡玛基因公司 制备重组人凝血酶的方法
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
WO2008051513A2 (en) 2006-10-23 2008-05-02 Allan Pronovost Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
AU2008233111A1 (en) 2007-03-30 2008-10-09 Thrombodyne, Inc. Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
NZ579985A (en) 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
CA2740079A1 (en) 2008-10-08 2010-04-15 Thrombodyne, Inc. Methods of making concentrated fibrinogen- and platelet-containing compositions
WO2012045569A1 (en) 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders

Also Published As

Publication number Publication date
JP6000259B2 (ja) 2016-09-28
HUE033204T2 (en) 2017-11-28
EP2624859B1 (en) 2017-03-01
DK2624859T3 (en) 2017-06-06
ES2625153T3 (es) 2017-07-18
CN103221061A (zh) 2013-07-24
RU2013120033A (ru) 2014-11-20
AU2011313505B2 (en) 2015-09-17
SG188639A1 (en) 2013-05-31
BR112013008034A2 (pt) 2016-06-14
EP2624859A1 (en) 2013-08-14
WO2012045569A9 (en) 2016-01-07
MX2013003715A (es) 2013-09-26
SG10201508159SA (en) 2015-10-29
PL2624859T3 (pl) 2017-09-29
AU2011313505A1 (en) 2013-04-11
US9433664B2 (en) 2016-09-06
WO2012045569A1 (en) 2012-04-12
RU2606155C2 (ru) 2017-01-10
JP2013538863A (ja) 2013-10-17
US20130280236A1 (en) 2013-10-24
MX343784B (es) 2016-11-23
CA2812888A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
KR20130136988A (ko) 지혈 장애를 치료하기 위한 인자 ii 및 피브리노겐
US20100279939A1 (en) Recombinant human fibrinogen for treatment of bleeding in trauma and platelet disorders
US20090018082A1 (en) Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma
CN110114074B (zh) 用于治疗或预防出血的凝血因子替代产品
KR20120022717A (ko) 피브리노겐의 신규 용도
HK1188391B (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
HK1188391A (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
Malhotra Spontaneous Subcutaneous Extracranial Bleed in Cirrhosis-A Rare Phenomenon
Marcucci et al. 11 Hematologic Risk Assessment
MXPA06008483A (en) Use of factor viia factor for treating trauma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130403

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160902

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171012

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180201

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171012

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I